IMMUNOCORE HOLDINGS PL

Immunocore Reports 2022 Financial Results and Provides Business Update

01 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

23 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV

22 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

01 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

09 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Immunocore is awarded the Prix Galien France award for KIMMTRAK

15 Dec 2022 05:00:00 By Nasdaq GlobeNewswire

Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

08 Dec 2022 05:30:00 By Nasdaq GlobeNewswire

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors

02 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

23 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

11 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the Jefferies London Healthcare Conference

10 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update

09 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

09 Sep 2022 09:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

10 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

03 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore Announces $140 Million Private Placement Financing

18 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

11 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

25 Jun 2022 03:00:00 By Nasdaq GlobeNewswire

Immunocore Appoints Siddharth Kaul to its Board of Directors

09 Jun 2022 06:45:00 By Nasdaq GlobeNewswire